Search clinical trials for: Pharmacokinetics, Dosage of Niraparib

Total 4289 results

Hospices Civils de Lyon

Recruiting

NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients. (NIRAPK)

Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer

France
Assistance Publique - Hôpitaux de Paris

Recruiting

Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT) (MYOCIT)

Juvenile Dermatomyositis

France
Tesaro, Inc.

Completed

Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer

Cancer

Netherlands
Tesaro, Inc.

Completed

Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule

Neoplasms

United States
Fudan University

Recruiting

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

Treatment Efficacy

China
Virginia Commonwealth University
GlaxoSmithKline; Puma Biotechnology, Inc.

Recruiting

Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE)

Ovarian Cancer | Advanced Solid Tumor

United States
P.O. Witteveen
Erasmus Medical Center; The Netherlands Cancer Institute

Terminated

Biomarker Development for Response Prediction by DNA Mutational Analysis (CPCT-01)

Neoplasm Metastasis

Netherlands
Sinovac Biotech Co., Ltd

Completed

Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine

Poliomyelitis

China
Centre Oscar Lambret

Completed

Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma (CILENT-0902)

Diffuse Intrinsic Pontine Glioma

France
Chongqing University Cancer Hospital

Recruiting

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer (CQGOG0101)

Cervical Cancer

China
Hunan Cancer Hospital

Unknown

A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer

Ovarian Cancer

China
German Breast Group
GlaxoSmithKline; Stemline Therapeutics, Inc.

Not yet recruiting

Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT)

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | Hormone Receptor Positive HER-2 Negative Breast Cancer | Advanced or Metastatic Breast Cancer

Germany
Sun Yat-sen University

Recruiting

Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

Population Pharmacokinetics/Pharmacodynamics of Carbapenems in Febrile Neutropenia Patients

Febrile Neutropenia | Pharmacokinetics | Pharmacodynamic | Carbapenems
Abramson Cancer Center at Penn Medicine

Active, not recruiting

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

Prostate Adenocarcinoma

United States
MedSIR

Not yet recruiting

Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (ANALLISA)

Ovarian Cancer | Oligometastatic Disease | Serous Ovarian Tumor
Institut Paoli-Calmettes
GlaxoSmithKline

Not yet recruiting

A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr (CAPRICE)

Breast Cancer
Lei Li

Recruiting

Niraparib Plus Anlotinib for Recurrent Ovarian Cancer

Chemotherapy | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Niraparib | Anlotinib | CA125 | Targeted Therapy | Recurrent Ovarian Cancer

China
Fundacion CRIS de Investigación para Vencer el...
GlaxoSmithKline; Apices Soluciones S.L.; Ipsen

Active, not recruiting

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA) (NICARAGUA)

Urothelial Cancer

Spain
Zai Lab (Shanghai) Co., Ltd.

Completed

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Ovarian Cancer

China
Creighton University

Completed

Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm

Atrial Fibrillation | Deep Vein Thrombosis | Pulmonary Embolism
David Liebner, MD

Withdrawn

Niraparib for the Treatment of Leiomyosarcoma

Locally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Stage III Retroperitoneal Sarcoma AJCC v8 | Stage IIIA Retroperitoneal Sarcoma AJCC v8 | Stage IIIB Retroperitoneal Sarcoma AJCC v8 | Stage IV Retroperitoneal Sarcoma AJCC v8

United States
University of Kansas Medical Center
Tesaro, Inc.

Active, not recruiting

Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial (NIRA-PANC)

Pancreatic Cancer

United States
Zai Lab (Shanghai) Co., Ltd.

Completed

A Study of Niraparib in Patients With Relapsed Ovarian Cancer

Ovarian Cancer

China
University of Alabama at Birmingham

Withdrawn

Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer (PARP)

Ovarian Cancer Recurrent

United States
University of Pennsylvania
Bristol-Myers Squibb; GlaxoSmithKline

Active, not recruiting

Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Parpvax)

Pancreatic Adenocarcinoma

United States
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway
Zai Lab (Shanghai) Co., Ltd.

Terminated

A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment

Gastric Cancer | Triple Negative Breast Cancer | Endometrial Carcinoma | Biliary Tract Carcinoma

China
Jiangsu Province Centers for Disease Control and...
Beijing Minhai Biotechnology Co., Ltd

Completed

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.

Polio and Post-Polio Syndrome

China
Sir Mortimer B. Davis - Jewish General Hospital

Not yet recruiting

Niraparib in High-grade Endometrial Cancer Trial (NIREC)

Endometrial Cancer | Uterine Neoplasm | Serous Adenocarcinoma
Myriad Genetic Laboratories, Inc.

Terminated

Study Comparing Optimized 5-FU Dosing and Standard Dosing in Metastatic Colorectal Cancer Patients Treated With mFOLFOX6 (PROFUSE)

Colorectal Cancer, Metastatic

United States
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States
University of Turin, Italy

Recruiting

UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC (UNITO-001)

Lung Cancer | Mesothelioma

Italy
Repare Therapeutics
Roche Pharma AG

Recruiting

Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid Tumors (ATTACC)

Advanced Solid Tumor, Adult

United States
Tesaro, Inc.
Merck Sharp & Dohme LLC

Completed

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO)

Neoplasms | Breast Cancer | Advanced Breast Cancer | Ovarian Cancer | Fallopian Tube Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Peritoneal Cancer | Stage IV Breast Cancer

United States
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
Tesaro, Inc.
European Organisation for Research and Treatment of Cancer - EORTC; Breast... and other collaborators

Terminated

A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO)

Ovarian Neoplasms | BRCA1 Gene Mutation | BRCA2 Gene Mutation | Neoplasms, Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Carcinoma of Breast

United States, Spain, Belgium, Israel, United Kingdom, Italy, Poland, Canada, Hungary, Netherlands, France, Portugal, Greece, Iceland
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Not yet recruiting

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy (SOPRANO)

Ovarian Cancer Recurrent

United Kingdom
ARCAGY/ GINECO GROUP
Tesaro, Inc.

Active, not recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)

Ovarian Carcinosarcoma | Endometrial Carcinosarcoma

France
University Hospital Southampton NHS Foundation...
British Lung Foundation; University of Southampton

Active, not recruiting

Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)

Mesothelioma, Malignant

United Kingdom
Ruijin Hospital
Cellular Biomedicine Group Ltd.

Unknown

A Clinical Study of Mesenchymal Stem Cell Exosomes Nebulizer for the Treatment of ARDS

Acute Respiratory Distress Syndrome

China
OHSU Knight Cancer Institute
Eli Lilly and Company; GlaxoSmithKline; Oregon Health and Science University

Active, not recruiting

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditions

United States
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
Marc Dall'Era, MD
National Cancer Institute (NCI); Janssen, LP

Recruiting

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Prostate Carcinoma | RAD51C Gene Mutation | BRIP1 Gene Mutation | ATM Gene Mutation | CHEK2 Gene Mutation | NBN Gene Mutation | RAD51 Gene Mutation | CDK12 Gene Mutation | CHEK1 Gene Mutation | DNA Damage Response Gene Mutation | DNA Repair Gene Mutation | FANCA Gene Mutation and other conditions

United States
Harvard School of Public Health (HSPH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Dietary Biomarkers Intervention Core

Diet, Healthy | Biological Markers | Nutrition, Healthy | Metabolomics

United States
Avera McKennan Hospital & University Health Center

Active, not recruiting

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Breast Cancer | Ovarian Cancer

United States
Hospital Israelita Albert Einstein

Unknown

Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation

Acute Leukemia | Immunodeficiency | Chronic Leukemia | Lymphoproliferative Disease | Myeloproliferative Disease

Brazil
Sun Yat-sen University

Recruiting

An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer Patients

Recurrent/ Advanced Stage Endometrial Cancer Patients

China
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

United States, Spain, Belgium, France, Korea, Republic of, United Kingdom
Beijing Nuokangda Pharmaceutical Technology Co....

Unknown

Phase I Clinical Study for Evaluation of Pharmacokinetic, Safety, Tolerance of Norcantharidin Lipid Microsphere for Injection in Patients With Solid Tumor

Solid Tumor

China

Search clinical trials for: Pharmacokinetics, Dosage of Niraparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations